Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LIPA | P38571 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655164 | 0.91 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL28773149 | 0.91 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL17047069 | 0.90 | CHRM1 (0.38) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL17047071 | 0.90 | CHRM1 (0.38) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL15777204 | 0.82 | FDPS (0.33) | LIPA | |
| Hydrochloric Acid SCHEMBL18952314 | 0.80 | FDPS (0.32) | KDM4ELIPA | |
| Hydrochloric Acid SCHEMBL20594071 | 0.80 | FDPS (0.32) | KDM4ELIPA | |
| Hydrochloric Acid SCHEMBL18952339 | 0.80 | FDPS (0.32) | KDM4ELIPA | |
| SCHEMBL3516359 | 0.76 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL21272723 | 0.76 | HMGCR (0.52) | HMGCRCHRM1TBXA2RADRA1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | HMGCR 4307/4885CHRM1 3997/4885TBXA2R 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.